What is Arbutus Biopharma Corporation's (ABUS) StockRank?

MoatMap's StockRank for Arbutus Biopharma Corporation (ABUS) is 81/100, with a Strong Buy signal. This is a composite score combining Quality (67), Value (50), and Momentum (51) factor ranks across MoatMap's 19,000+ stock universe.

Does Arbutus Biopharma Corporation have an economic moat?

Arbutus Biopharma Corporation (ABUS) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Arbutus Biopharma Corporation a buy, hold, or sell?

MoatMap's current signal for Arbutus Biopharma Corporation (ABUS) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Arbutus Biopharma Corporation in?

Arbutus Biopharma Corporation (ABUS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ABUS

STRONG BUYREMOVE

Arbutus Biopharma Corporation · Healthcare · United States · $909M · Avg Vol: $6M/d

StockRank

P/E (TTM)

5.1x

ROE

94.7%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Arbutus Biopharma is a clinical-stage biotech focused on HBV. It does not fit the CDMO pricing power theme and is a high-risk, pre-revenue binary bet that violates our Terry Smith quality compounder lens.

COMPANY DESCRIPTION

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics for chronic hepatitis B virus (HBV) infection. The company's competitive advantage stems from its proprietary pipeline of differentiated drug candidates, including RNA interference (RNAi) and capsid assembly inhibitors, which target multiple stages of the HBV lifecycle and address a significant global unmet medical need within a specialized therapeutic area.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	CAGR
Revenue	11M	39M	18M	6M	-17.5%
EPS	-0.83	-0.46	-0.44	-0.38	—
Shares	145M	157M	170M	190M	+31.0%
Debt	3M	2M	2M	1M	-21.0%
Equity	169M	137M	106M	97M	-16.9%
Op CF	-68M	-35M	-86M	-65M	—
Inv CF	-13M	-75M	51M	23M	—
Fin CF	137M	32M	31M	52M	—

PRICE (1M)-1.4%

SMA 50SMA 200

$4.26

RSI (14)

46.3

52W High

$5.10

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-37.7%18.3

ROE

94.7%99.0

GP/Assets

180.8%98.6

Op. Margin

94.4%99.6

FCF/Assets

-95.5%1.3

Piotroski

—28.8

Int. Cover

-50.0x6.5

D/E Ratio

0.02x85.2

Current Ratio

54.26x99.3

Value

P/E (TTM)

5.1x96.4

EV/EBITDA

4.8x57.7

P/FCF

—N/A

P/B

3.2x37.0

P/S

4.4x44.6

Div Yield

—N/A

Momentum

52W High %

84%79.5

RS 6M

-16%61.7

SMA 50/200

0.99x60.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-120%3.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$909M

P/E (Forward)

-25.8x

Gross Margin

89.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABUS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ABUS	Arbutus Biopharma Corporation(you)	$909M	81	STRONG BUY
TBPH	Theravance Biopharma, Inc.	$836M	72	BUY
KALV	KalVista Pharmaceuticals, Inc.	$1.4B	74	BUY
URGN	UroGen Pharma Ltd.	$1.4B	73	BUY
CRMD	CorMedix Inc.	$661M	92	STRONG BUY
RIGL	Rigel Pharmaceuticals, Inc.	$556M	91	STRONG BUY
ZVRA	Zevra Therapeutics, Inc.	$674M	96	STRONG BUY
MGTX	MeiraGTx Holdings plc	$926M	59	HOLD
RLMD	Relmada Therapeutics, Inc.	$760M	59	HOLD
MDXG	MiMedx Group, Inc.	$547M	65	BUY

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.2%

Arbutus Biopharma Corporation (ABUS) — Stock Score Summary

Arbutus Biopharma Corporation (ABUS) has a MoatMap StockRank of 81/100 based on Quality (67/100), Value (50/100), and Momentum (51/100) factor scores. The current signal is STRONG BUY. Arbutus Biopharma is a clinical-stage biotech focused on HBV. It does not fit the CDMO pricing power theme and is a high-risk, pre-revenue binary bet that violates our Terry Smith quality compounder lens.

Key Financial Metrics

Price	$4.26
Market Cap	$909M
P/E (TTM)	5.13
P/E (Forward)	-25.77
Price/Book	3.22
Return on Equity	94.7%
Return on Invested Capital	-37.7%
Debt/Equity	1.50
Gross Margin	89.3%
Operating Margin	94.4%
Revenue Growth	10054.5%
Free Cash Flow	$-90M

Arbutus Biopharma Corporation operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Arbutus Biopharma Corporation’s (ABUS) StockRank?: MoatMap’s StockRank for Arbutus Biopharma Corporation (ABUS) is 81/100, with a Strong Buy signal. It is a composite of Quality (67), Value (50), and Momentum (51) factor ranks across MoatMap’s 19,000+ stock universe.
Does Arbutus Biopharma Corporation have an economic moat?: Arbutus Biopharma Corporation (ABUS) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Arbutus Biopharma Corporation a buy, hold, or sell?: MoatMap’s current signal for Arbutus Biopharma Corporation (ABUS) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Arbutus Biopharma Corporation in?: Arbutus Biopharma Corporation (ABUS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).